Sunitinib causes dose-dependent negative functional effects on myocardium and cardiomyocytes
Peter P Rainer1, Bernhard Doleschal, Jonathan A Kirk
1Division of Cardiology, Department of Internal Medicine, Medical University Graz, Austria.
BJU International
|April 18, 2012
Summary
Sunitinib significantly reduces heart muscle contractility and increases reactive oxygen species (ROS) in a dose-dependent manner. This study investigated sunitinib
Area of Science:
- Cardiology
- Pharmacology
- Molecular Biology
Background:
- Sunitinib is a tyrosine kinase inhibitor used in cancer therapy.
- Cardiotoxicity is a known side effect of some targeted cancer therapies.
- Understanding the mechanisms of sunitinib-induced cardiotoxicity is crucial for patient safety.
Purpose of the Study:
- To investigate the acute effects of sunitinib on cardiac function, including inotropic function and intracellular calcium handling.
- To assess the generation of reactive oxygen species (ROS) in response to sunitinib exposure.
- To explore microRNAs as potential biomarkers for sunitinib-induced cardiotoxicity.
Main Methods:
- Isolated human myocardium and mouse cardiomyocytes were exposed to varying concentrations of sunitinib.
- Cardiac contractility, intracellular calcium transients, and ROS generation were measured.
- MicroRNA expression was analyzed using microarray and real-time PCR.
Main Results:
- Sunitinib caused a dose-dependent decrease in developed force and sarcomere shortening.
- Intracellular calcium transients were significantly reduced, while ROS levels increased.
- Myofilament calcium sensitivity remained unchanged, and microRNA expression patterns were not altered.
Conclusions:
- Sunitinib exerts a negative inotropic effect on the myocardium, associated with reduced intracellular calcium and elevated ROS.
- These cardiotoxic effects warrant consideration in clinical settings, especially when sunitinib concentrations may be elevated.
- MicroRNAs did not emerge as reliable biomarkers for sunitinib-induced cardiac toxicity in this study.
More Related Videos
13:19Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
Published on: April 26, 2024
09:32Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity
Published on: October 17, 2025
Related Concept Videos
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:26Heart Failure Drugs: Inotropic Agents
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
01:24Drug Toxicity: Dose-Dependent Reactions
Drug toxicities can be stratified into pharmacological, pathological, or genotoxic based on their mechanisms. The incidence and severity of these toxicities generally increase with the drug's concentration in the body and exposure time.Pharmacological toxicity is evident when the therapeutic effects of drugs overshoot into adverse reactions in a predictable, dose-dependent manner. Central nervous system (CNS) depression from barbiturates is a classic example, with effects escalating from...
01:12Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...
01:22Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
01:22Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...